INT206764

From wiki-pain
(Difference between revisions)
Jump to: navigation, search
(Generated page)
(Generated page)
 
(One intermediate revision by one user not shown)
Line 10: Line 10:
 
|-
 
|-
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| First Reported
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| First Reported
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 
|-
 
|-
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Last Reported
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Last Reported
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
|-
 
|-
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Negated
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Negated
Line 31: Line 31:
 
|-
 
|-
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 13.44812
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 13.45
 
|-
 
|-
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 5.01142
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 2.84
 
|-
 
|-
 
|}
 
|}
Line 48: Line 48:
 
fontcolor=white,
 
fontcolor=white,
 
label="Binding",
 
label="Binding",
URL=Binding
+
URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=E:Binding"
 
];
 
];
 
node2
 
node2
Line 56: Line 56:
 
fontcolor=white,
 
fontcolor=white,
 
label="AQP4",
 
label="AQP4",
URL="AQP4"
+
URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=G:361"
 
];
 
];
 
node3
 
node3
Line 64: Line 64:
 
fontcolor=white,
 
fontcolor=white,
 
label="Nqo1",
 
label="Nqo1",
URL="Nqo1"
+
URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=G:18104"
 
];
 
];
 
subgraph cluster_0 {
 
subgraph cluster_0 {
Line 78: Line 78:
 
{| cellspacing=5 cellpadding=2
 
{| cellspacing=5 cellpadding=2
 
|-
 
|-
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[cytoplasm]] ([[AQP4]], [[Nqo1]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:cytoplasm|cytoplasm]] ([[G:361|AQP4]], [[G:18104|Nqo1]])
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[cytosol]] ([[Nqo1]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:cytosol|cytosol]] ([[G:18104|Nqo1]])
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[transport]] ([[AQP4]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:transport|transport]] ([[G:361|AQP4]])
 
|-
 
|-
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[oxidoreductase activity]] ([[Nqo1]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:oxidoreductase activity|oxidoreductase activity]] ([[G:18104|Nqo1]])
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[plasma membrane]] ([[AQP4]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:plasma membrane|plasma membrane]] ([[G:361|AQP4]])
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[transmembrane transport]] ([[AQP4]])
+
| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:transmembrane transport|transmembrane transport]] ([[G:361|AQP4]])
 
|-
 
|-
 
|}
 
|}
Line 102: Line 102:
 
|}
 
|}
 
{| cellspacing=2 cellpadding=2
 
{| cellspacing=2 cellpadding=2
|
+
| style="vertical-align: top"|
 
{| cellspacing=1 cellpadding=5 align=center
 
{| cellspacing=1 cellpadding=5 align=center
 
|-
 
|-
! style="color: black; background:#AAFCFB; white-space:wrap;"| Pain Term
+
! style="color: black; background:#AAFCFB; white-space:wrap;"| Pain Link
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
! style="color: black; background:#AAFCFB; white-space:wrap;"| Confidence
+
! style="color: black; background:#AAFCFB; white-space:wrap;"| Relevance
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Multiple sclerosis]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Multiple sclerosis|Multiple sclerosis]]
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
+
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
 +
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Demyelination]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Demyelination|Demyelination]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 16
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 16
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.46
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.46
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[medulla]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:medulla|medulla]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 95.96
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 95.96
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Spinal cord]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Spinal cord|Spinal cord]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 52
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 52
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.32
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.32
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Central nervous system]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Central nervous system|Central nervous system]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[addiction]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:addiction|addiction]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 9
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 9
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 84.08
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 84.08
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Neuritis]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Neuritis|Neuritis]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 81.76
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 81.76
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[imagery]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:imagery|imagery]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 10
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 10
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 74.52
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 74.52
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Inflammation]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Inflammation|Inflammation]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 59
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 59
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 60.48
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 60.48
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[intrathecal]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:intrathecal|intrathecal]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 53.36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 53.36
Line 163: Line 163:
 
|}
 
|}
 
|
 
|
|
+
| style="vertical-align: top"|
 
{| cellspacing=1 cellpadding=5 align=center
 
{| cellspacing=1 cellpadding=5 align=center
 
|-
 
|-
! style="color: black; background:#AAFCFB; white-space:wrap;"| Disease Term
+
! style="color: black; background:#AAFCFB; white-space:wrap;"| Disease Link
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
! style="color: black; background:#AAFCFB; white-space:wrap;"| Confidence
+
! style="color: black; background:#AAFCFB; white-space:wrap;"| Relevance
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
 
! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Demyelinating Disease]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Neuromyelitis Optica|Neuromyelitis Optica]]
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 220
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 481
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Neuromyelitis Optica]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Demyelinating Disease|Demyelinating Disease]]
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 481
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 220
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Necrosis]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Necrosis|Necrosis]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 6
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 6
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.7
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.70
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Autonomic Nervous System Disease]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Autonomic Nervous System Disease|Autonomic Nervous System Disease]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97.36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97.36
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Disease]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Disease|Disease]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 261
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 261
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 96.04
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 96.04
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Respiratory Failure]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Respiratory Failure|Respiratory Failure]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 94.08
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 94.08
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Autoimmune Disease]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Autoimmune Disease|Autoimmune Disease]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 19
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 19
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.68
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.68
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Channelopathies]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Channelopathies|Channelopathies]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 91.72
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 91.72
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Central Nervous System Disease]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Central Nervous System Disease|Central Nervous System Disease]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 22
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 22
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
 
|-
 
|-
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Syndrome]]
+
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Syndrome|Syndrome]]
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 24
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 24
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 87.52
 
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 87.52
Line 240: Line 240:
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| Lennon and colleagues discovered a biomarker for NMO; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which <span style="background-color:#B0E0E6">binds</span> to aquaporin-4 (<span style="background-color:#FFFF00">AQP4</span>) [11], the most abundant water channel in the CNS [12-14].  
+
| Lennon and colleagues discovered a biomarker for <span style="background-color:#FFA07A">NMO</span>; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of <span style="background-color:#FFA07A">NMO</span> but less than 5% of <span style="background-color:#FFA07A">CMS</span> patients [10], which <span style="background-color:#B0E0E6">binds</span> to aquaporin-4 (<span style="background-color:#FFFF00">AQP4</span>) [11], the most abundant water channel in the CNS [12-14].  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binds</span>) of <span style="color:#800000">'''NMO-IgG'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binds</span>) of [[G:18104|<span style="color:#800000">'''NMO-IgG'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span> and <span style="color:#FF0000">'''multiple sclerosis'''</span>
 
|-
 
|-
 
|}
 
|}
Line 256: Line 256:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
Line 264: Line 264:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2.72
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.75
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| Lennon and colleagues discovered a biomarker for NMO; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which <span style="background-color:#B0E0E6">binds</span> to <span style="background-color:#FFFF00">aquaporin-4</span> (AQP4) [11], the most abundant water channel in the CNS [12-14].  
+
| Lennon and colleagues discovered a biomarker for <span style="background-color:#FFA07A">NMO</span>; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of <span style="background-color:#FFA07A">NMO</span> but less than 5% of <span style="background-color:#FFA07A">CMS</span> patients [10], which <span style="background-color:#B0E0E6">binds</span> to <span style="background-color:#FFFF00">aquaporin-4</span> (AQP4) [11], the most abundant water channel in the CNS [12-14].  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''aquaporin-4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binds</span>) of <span style="color:#800000">'''NMO-IgG'''</span>
+
|  [[G:361|<span style="color:#800000">'''aquaporin-4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binds</span>) of [[G:18104|<span style="color:#800000">'''NMO-IgG'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span> and <span style="color:#FF0000">'''multiple sclerosis'''</span>
 
|-
 
|-
 
|}
 
|}
Line 287: Line 287:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
Line 295: Line 295:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2.72
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.74
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| Thus we hypothesized that <span style="background-color:#FFFF00">AQP4</span> antibodies in fact <span style="background-color:#B0E0E6">characterize</span> <span style="background-color:#FFFF00">NMO</span> patients.
+
| Thus we hypothesized that <span style="background-color:#FFFF00">AQP4</span> antibodies in fact <span style="background-color:#B0E0E6">characterize</span> <span style="background-color:#FFA07A">NMO</span> patients.
  
  
Line 309: Line 309:
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">characterize</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">characterize</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 
|-
 
|-
 
|}
 
|}
Line 320: Line 320:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
Line 328: Line 328:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.17
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.17
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| It is therefore still unclear whether antibodies to <span style="background-color:#FFFF00">AQP4</span> are <span style="background-color:#B0E0E6">specific</span> for <span style="background-color:#FFFF00">NMO</span> and whether testing for these antibodies may be useful for its diagnosis and its distinction from diseases with similar clinical and neuroradiological patterns, such as MS and other autoimmune diseases with involvement of the CNS.  
+
| It is therefore still unclear whether antibodies to <span style="background-color:#FFFF00">AQP4</span> are <span style="background-color:#B0E0E6">specific</span> for <span style="background-color:#FFA07A">NMO</span> and whether testing for these antibodies may be useful for its diagnosis and its distinction from <span style="background-color:#FFA07A">diseases</span> with similar clinical and neuroradiological patterns, such as <span style="background-color:#FFA07A">MS</span> and other <span style="background-color:#FFA07A">autoimmune diseases</span> with involvement of the <span style="background-color:#FFA07A">CNS</span>.  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">specific</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">specific</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>, <span style="color:#FF0000">'''multiple sclerosis'''</span>, <span style="color:#FF0000">'''autoimmune disease'''</span>, <span style="color:#FF0000">'''central nervous system'''</span> and <span style="color:#FF0000">'''disease'''</span>
 
|-
 
|-
 
|}
 
|}
Line 351: Line 351:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
Line 359: Line 359:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.74
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.29
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| The limited access of circulating IgG to the extracapillary space in the CNS would only permit <span style="background-color:#B0E0E6">interaction</span> of <span style="background-color:#FFFF00">NMO</span>-IgG with <span style="background-color:#FFFF00">AQP4</span> at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.  
+
| The limited access of circulating IgG to the extracapillary space in the CNS would only permit <span style="background-color:#B0E0E6">interaction</span> of <span style="background-color:#FFA07A">NMO</span>-IgG with <span style="background-color:#FFFF00">AQP4</span> at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">interaction</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">interaction</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 
|-
 
|-
 
|}
 
|}
Line 382: Line 382:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
Line 390: Line 390:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.09
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.17
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| Moreover, two pathologic patterns in <span style="background-color:#FFFF00">NMO</span>, both of which were <span style="background-color:#B0E0E6">associated</span> with loss of <span style="background-color:#FFFF00">AQP4</span> immunoreactivity were described [39].  
+
| Moreover, two pathologic patterns in <span style="background-color:#FFA07A">NMO</span>, both of which were <span style="background-color:#B0E0E6">associated</span> with loss of <span style="background-color:#FFFF00">AQP4</span> immunoreactivity were described [39].  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 
|-
 
|-
 
|}
 
|}
Line 413: Line 413:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
Line 421: Line 421:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.33
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.35
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of demyelination or necrosis suggests that <span style="background-color:#B0E0E6">binding</span> of antibody to <span style="background-color:#FFFF00">AQP4</span> may be the initial pathogenic event in <span style="background-color:#FFFF00">NMO</span> lesions.
+
| In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of <span style="background-color:#FFA07A">demyelination</span> or <span style="background-color:#FFA07A">necrosis</span> suggests that <span style="background-color:#B0E0E6">binding</span> of antibody to <span style="background-color:#FFFF00">AQP4</span> may be the initial pathogenic event in <span style="background-color:#FFA07A">NMO</span> lesions.
  
 
|-
 
|-
Line 434: Line 434:
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binding</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binding</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>, <span style="color:#FF0000">'''necrosis'''</span> and <span style="color:#FF0000">'''demyelination'''</span>
 
|-
 
|-
 
|}
 
|}
Line 445: Line 445:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
Line 453: Line 453:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.27
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.31
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| In 70-80% of cases, neuromyelitis optica (<span style="background-color:#FFFF00">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to <span style="background-color:#FFFF00">aquaporin-4</span> (termed AQP4-Ab or NMO-IgG).  
+
| In 70-80% of cases, <span style="background-color:#FFA07A">neuromyelitis optica</span> (<span style="background-color:#FFA07A">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to <span style="background-color:#FFFF00">aquaporin-4</span> (termed AQP4-Ab or <span style="background-color:#FFA07A">NMO</span>-IgG).  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''aquaporin-4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''aquaporin-4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 
|-
 
|-
 
|}
 
|}
Line 476: Line 476:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
Line 484: Line 484:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.70
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
|}
 
|}
 
|-
 
|-
 
|}
 
|}
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
 
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
| In 70-80% of cases, neuromyelitis optica (<span style="background-color:#FFFF00">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to aquaporin-4 (termed <span style="background-color:#FFFF00">AQP4</span>-Ab or NMO-IgG).  
+
| In 70-80% of cases, <span style="background-color:#FFA07A">neuromyelitis optica</span> (<span style="background-color:#FFA07A">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to aquaporin-4 (termed <span style="background-color:#FFFF00">AQP4</span>-Ab or <span style="background-color:#FFA07A">NMO</span>-IgG).  
 
|-
 
|-
 
|
 
|
 
{| cellpadding=4 cellspacing=2  
 
{| cellpadding=4 cellspacing=2  
 
|-
 
|-
| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+
|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 
|-
 
|-
 
|}
 
|}
Line 507: Line 507:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
Line 515: Line 515:
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
 
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.70
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
 
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 
|}
 
|}
 
|-
 
|-

Latest revision as of 23:29, 20 September 2012

Context Info
Confidence 0.05
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 13.45
Pain Relevance 2.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (AQP4, Nqo1) cytosol (Nqo1) transport (AQP4)
oxidoreductase activity (Nqo1) plasma membrane (AQP4) transmembrane transport (AQP4)
AQP4 (Homo sapiens)
Nqo1 (Mus musculus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 100 100.00 Very High Very High Very High
Demyelination 16 99.46 Very High Very High Very High
medulla 2 95.96 Very High Very High Very High
Spinal cord 52 92.32 High High
Central nervous system 36 90.92 High High
addiction 9 84.08 Quite High
Neuritis 97 81.76 Quite High
imagery 10 74.52 Quite High
Inflammation 59 60.48 Quite High
intrathecal 36 53.36 Quite High
Disease Link Frequency Relevance Heat
Neuromyelitis Optica 481 100.00 Very High Very High Very High
Demyelinating Disease 220 100.00 Very High Very High Very High
Necrosis 6 99.70 Very High Very High Very High
Autonomic Nervous System Disease 2 97.36 Very High Very High Very High
Disease 261 96.04 Very High Very High Very High
Respiratory Failure 5 94.08 High High
Autoimmune Disease 19 92.68 High High
Channelopathies 2 91.72 High High
Central Nervous System Disease 22 90.92 High High
Syndrome 24 87.52 High High

[edit] Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].
AQP4 Binding (binds) of NMO-IgG associated with neuromyelitis optica and multiple sclerosis
1) Confidence 0.05 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 2.72 Pain Relevance 0.75
Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].
aquaporin-4 Binding (binds) of NMO-IgG associated with neuromyelitis optica and multiple sclerosis
2) Confidence 0.05 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 2.72 Pain Relevance 0.74
Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients.


AQP4 Binding (characterize) of NMO associated with neuromyelitis optica
3) Confidence 0.03 Published 2007 Journal PLoS Medicine Section Abstract Doc Link PMC1852124 Disease Relevance 1.17 Pain Relevance 0.17
It is therefore still unclear whether antibodies to AQP4 are specific for NMO and whether testing for these antibodies may be useful for its diagnosis and its distinction from diseases with similar clinical and neuroradiological patterns, such as MS and other autoimmune diseases with involvement of the CNS.
AQP4 Binding (specific) of NMO associated with neuromyelitis optica, multiple sclerosis, autoimmune disease, central nervous system and disease
4) Confidence 0.03 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1852124 Disease Relevance 1.74 Pain Relevance 0.29
The limited access of circulating IgG to the extracapillary space in the CNS would only permit interaction of NMO-IgG with AQP4 at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.
AQP4 Binding (interaction) of NMO associated with neuromyelitis optica
5) Confidence 0.02 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.09 Pain Relevance 0.17
Moreover, two pathologic patterns in NMO, both of which were associated with loss of AQP4 immunoreactivity were described [39].
AQP4 Binding (associated) of NMO associated with neuromyelitis optica
6) Confidence 0.02 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.33 Pain Relevance 0.35
In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of demyelination or necrosis suggests that binding of antibody to AQP4 may be the initial pathogenic event in NMO lesions.
AQP4 Binding (binding) of NMO associated with neuromyelitis optica, necrosis and demyelination
7) Confidence 0.02 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.27 Pain Relevance 0.31
In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).
aquaporin-4 Binding (associated) of NMO associated with neuromyelitis optica
8) Confidence 0.01 Published 2010 Journal J Neuroinflammation Section Abstract Doc Link PMC2945323 Disease Relevance 0.70 Pain Relevance 0.03
In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).
AQP4 Binding (associated) of NMO associated with neuromyelitis optica
9) Confidence 0.01 Published 2010 Journal J Neuroinflammation Section Abstract Doc Link PMC2945323 Disease Relevance 0.70 Pain Relevance 0.03

[edit] General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox